Drs. Misaki Kiguchi and Kyle Reynolds (@KReyMD) review several of the most impactful deep venous trials to date to help better understand current guidelines and what the future looks like. https://t.co/5nMc2EsSqU
@JenniferSvahnMD@VascularSVS@NickMouawadMD@DejahJudelson There are some great ongoing studies re: this Q. It depends on presentation of disease (cosmetic v symptoms v trophic changes). I image early if there is a high suspicion of IF disease (DVT hx, prior IF stent). #SVSTweetChat
@VascularSVS@NickMouawadMD@JenniferSvahnMD@DejahJudelson Treating acute IF-DVT can be about both reducing PTS incidence and rapidly restoring QOL. Underlying pathology dictates my approach - PTS and acute clot, thrombosed stents v. first time clot can all respond to mechanical or lytic-based approach. #SVSTweetChat